V-DEL Platform

Discovery Biology Services

Hmoe / CRO Services / Discovery Biology Services / Hit Discovery / V-DEL Platform

V-DEL Platform

The V-DEL platform, led by our seasoned DEL experts, showcases high-quality DEL libraries and screening methods with high success rate. This platform integrates with Viva Biotech's comprehensive one-stop drug discovery solution, supported by advanced methodologies such as AIDD/CADD. It further synergizes with SBDD/FBDD and incorporates technologies like ASMS, SPR, X-Ray Crystallography, and Cryo-EM, offering a wide range of services. These include target protein production, customized DEL synthesis, affinity selection, follow-up synthesis, hit confirmation and assay development, medicinal chemistry as well as CDMO services. This holistic approach is designed to expedite the discovery of both FIC and BIC drugs.

High-purity, diverse protein

A top protein R&D platform with efficiency and scale.

Proprietary technologies for membrane protein expression and lipid nanodiscs preparation.

High-grade, differential V-DELs

High-quality V-DELs (>100 billion diversity) with innovative strategies and on-DNA reactions.

Leveraging our med chem engine’s collection of large numbers of un-commercially available building blocks (~26,000)

High-quality, fast delivery

5 weeks from Screening to Validatio

1,500 fume hoods

Supported by Viva Biotech’s med chem engine.

Shortened the timelines for both DEL synthesis and off-DNA re-synthesis.

Well-established confirmation process

Viva is a highly experienced provider of ASMS and SPR validation for DEL hits

Well-proven synergetic and holistic strategy

AIDD/CADD powered

Developed synergistic approaches, such as (DEL+FBDD/SBDD) and (DEL + FEP calculation)

Significantly boosts the success rate of DEL screening and its follow-up investigation.

Access to expertise across the organization

The below is the punch line, suggest to keep it as a whole.While you work with one platform at Viva, our entire team of experts with rich experience spanning nearly 20 platforms (including protein production, ASMS, SPR, X-ray crystallography, Cryo-EM, FBDD, SBDD, medicinal chemistry, ADME-PK, AIDD/CADD, and CDMO) is always accessible.

V-DEL libraries: High quality
Design

Generic& proprietary DELs such as PROTAC, fragmen, cyclopeptide, and warheadless

Target focused or Customized DEls (co-design with clients)

DELs with more diversified and drug like chem space using:

novel or milder on DNA compatible reactions (on top of >50 routinely implemented);

BBs (from>26,000) & scaffoids (from>5000) recommended/analyzed by Al/ML/cheminformatics

Validation

BB Validation

Scaffold Synthesis and Validation

Route Optimization

Mini Library Validation

Timeline: 1 month, for brand new customized DELs

Production

Ligation (strict QC)

Chemistry (strict QC)

HPLC purifications

QC strategies

Gel electrophoresis

LCMS

Parallel single tube production

Parallel small-scale DEL production

qPCR

BBQC

Timeline: 1to 2months

QC

Heavy Metal Residues Analysis

qPCR

NGS Analysis (one of the most stringent standards across the indurstry)
DNA-Compatible reactions/Tool box
>50 Reactions for library construction
Couplings

Suzuki

Heck

Buchwald

Sonogashira

Deprotections

De-Boc

De-Alloc

De-Fmoc

NO2 reduction

Ester hydrolysis

Cyclizations

Click

Tetrazole

Hydantoin

Indole formation

Benzimidazolone

Imidazolidin-2-one

Imidazole formation

Macrocyclic peptide

Pictet-Spengler reaction

Benzimidazole formation

Quinazolinone formation

Groebke-Blackburn-

Bienaymé reaction

Reactions with amines

SN2

SNAr

Urea formation

Michael addition

Reactions with aldehyes

Wittig reaction

Oxidative amidation

Reductive amination

Amine capping

Amidation

Sulfonylation

Urea formation

Reductive amination

Carbamate formation
Functional groups
Acids

Amines

Amino acids

Fmoc amino acids

Aldehydes

Alcohols

Aryl halides

Boronates

Sulfonyl chlorides

Active aromatic halides

^*Total 26000+BBs
V-DEL screening: High success rate
V-DEL powered SBDD/FBDD and SBDD/FBDD powered V-DELD
Case Study: Unknown Target Screening

Online Message

After receiving your message, our professional team will contact you shortly.

Area of Interest

CRO Drug R&D Services

CDMO R&D and Production Services

EFS Investment＆Incubation Business

Media Cooperation

Investor Relations

Other

How Did You Hear About Us?

Search Engine (Google, Bing, Yahoo, etc)

Conferences/Events

Social Media

LinkedIn

Word of Mouth

Other

For more information about

“Hit Discovery”, please contact our team.